Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection
- PMID: 11317252
- DOI: 10.1086/320166
Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection
Abstract
Tolerability of the combination of zidovudine, lamivudine, and nelfinavir used as postexposure prophylaxis (PEP) for HIV infection was prospectively evaluated among 185 patients at 11 hospitals in eastern France. After exclusion of the 106 persons who discontinued PEP either because the source patient subsequently tested HIV seronegative or because the injury was reassessed as resulting in a low risk for transmission of HIV, 67 (85%) of the patients who received such PEP experienced adverse effects, which led to withdrawal of nelfinavir in 28 (35%) of these patients.
Similar articles
-
Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.Clin Infect Dis. 2005 Jan 15;40(2):303-5. doi: 10.1086/426589. Epub 2004 Dec 21. Clin Infect Dis. 2005. PMID: 15655751 Clinical Trial.
-
Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.Clin Infect Dis. 2001 Jun 1;32(11):1635-6. doi: 10.1086/320528. Epub 2001 Apr 30. Clin Infect Dis. 2001. PMID: 11340537
-
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).Antivir Ther. 2002 Jun;7(2):81-90. Antivir Ther. 2002. PMID: 12212928 Clinical Trial.
-
Lamivudine for the treatment of HIV.Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):105-14. doi: 10.1517/17425250903490418. Expert Opin Drug Metab Toxicol. 2010. PMID: 20001611 Review.
-
[Early treatment of sexual exposure to human immunodeficiency virus].Ann Dermatol Venereol. 2000 Jan;127(1):122-4. Ann Dermatol Venereol. 2000. PMID: 10717578 Review. French. No abstract available.
Cited by
-
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP).Open Forum Infect Dis. 2023 Jul 19;10(8):ofad374. doi: 10.1093/ofid/ofad374. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37539061 Free PMC article.
-
Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.BMC Infect Dis. 2016 Nov 29;16(1):718. doi: 10.1186/s12879-016-2056-3. BMC Infect Dis. 2016. PMID: 27894270 Free PMC article.
-
Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.BMC Public Health. 2015 Jun 20;15:573. doi: 10.1186/s12889-015-1928-6. BMC Public Health. 2015. PMID: 26092496 Free PMC article.
-
Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting.Eur J Epidemiol. 2004;19(6):577-84. doi: 10.1023/b:ejep.0000032349.57057.8a. Eur J Epidemiol. 2004. PMID: 15330131 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous